Invatec gains access to US market with ev3 deal:
This article was originally published in Clinica
Executive Summary
Italian company Invatec has appointed Plymouth, Minnesota-based ev3 as exclusive distributor of its endovascular products in the US. The deal represents Brescia-based company's entry into this significant market for the first time. Invatec will also team up with ev3 to commercialise Invatec's new technology aimed at the embolic protection and thrombectomy markets. ev3, a young, privately-held company involved in developing endovascular technologies, will see its product line expand with this new alliance, particularly in the areas of peripheral angioplasty balloon catheters, balloon-expandable and self-expanding stent systems and guidewires.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.